drugset / Trial / NCT02357615

Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Early Morning Blood Pressure and Central Arterial Pressure

NCT02357615

Phase 4 Unknown 244 enrolled Shanghai Shyndec Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare nifedipine controlled-release (CR) tablets (Xin Ran) with nifedipine controlled-release tablets (Adalat)in the treatment of Early Morning Blood Pressure and Central Arterial Pressure.

Timeline

Start
2014-12
Primary completion
2015-06
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Nifedipine Other / unclassified 30 mg Oral